Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramon 194, 20014 Donostia-San Sebastián, Spain; POLYMAT, Applied Chemistry Department, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel de Lardizabal 3, 20018 Donostia-San Sebastián, Spain.
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramon 194, 20014 Donostia-San Sebastián, Spain.
Int J Pharm. 2024 Mar 25;653:123864. doi: 10.1016/j.ijpharm.2024.123864. Epub 2024 Feb 1.
Gene therapy can potentially treat a great number of diseases, from cancer to rare genetic disorders. Very recently, the development and emergency approval of nucleic acid-based COVID-19 vaccines confirmed its strength and versatility. However, gene therapy encounters limitations due to the lack of suitable carriers to vectorize therapeutic genetic material inside target cells. Nanogels are highly hydrated nano-size crosslinked polymeric networks that have been used in many biomedical applications, from drug delivery to tissue engineering and diagnostics. Due to their easy production, tunability, and swelling properties they have called the attention as promising vectors for gene delivery. In this review, nanogels are discussed as vectors for nucleic acid delivery aiming to enlarge gene therapy's therapeutic window. Recent works highlighting the optimization of inherent transfection efficiency and biocompatibility are reviewed here. The importance of the monomer choice, along with the internal structure, surface decoration, and responsive features are outlined for the different transfection modalities. The possible sources of toxicological endpoints in nanogels are analyzed, and the strategies to limit them are compared. Finally, perspectives are discussed to identify the remining challenges for the nanogels before their translation to the market as transfection agents.
基因治疗有可能治疗许多疾病,从癌症到罕见的遗传疾病。就在最近,基于核酸的 COVID-19 疫苗的开发和紧急批准证实了其强大性和多功能性。然而,由于缺乏合适的载体将治疗性遗传物质载体化到靶细胞内,基因治疗遇到了限制。纳米凝胶是高度水合的纳米尺寸交联聚合物网络,已被用于许多生物医学应用,从药物输送到组织工程和诊断。由于其易于生产、可调性和溶胀特性,它们被称为基因传递的有前途的载体。在这篇综述中,纳米凝胶被讨论为核酸传递载体,旨在扩大基因治疗的治疗窗口。这里回顾了最近强调优化内在转染效率和生物相容性的工作。对于不同的转染方式,单体选择、内部结构、表面修饰和响应特性的重要性被概述。分析了纳米凝胶中可能出现毒性终点的来源,并比较了限制这些终点的策略。最后,讨论了纳米凝胶在作为转染剂推向市场之前仍需解决的挑战的观点。